National Guideline Clearinghouse | Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis.

Guideline Title
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis.

Bibliographic Source(s)
National Institute for Health and Clinical Excellence (NICE). Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2010 Aug. 35 p. (Technology appraisal guidance; no. 199).

Guideline Status
This is the current release of the guideline.

This guideline updates previous versions: National Institute for Health and Clinical Excellence (NICE). Adalimumab for the treatment of psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Aug. 26 p. (Technology appraisal guidance; no. 125).

National Institute for Health and Clinical Excellence (NICE). Etanercept and infliximab for the treatment of adults with psoriatic arthritis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2006 Jul. 33 p. (Technology appraisal guidance; no. 104).

full-text:
National Guideline Clearinghouse | Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis.